Genovis is moving to new premises

Genovis and the wholly owned subsidiary GeccoDots are joining forces and moving
in September from their premises in Lund and Malmö, respectively, to new
premises in Medicon Village, Lund.

“The new premises are ideal for our operations and the Medicon Village concept
opens the door for inspiring meetings between academia, new technology and
business. Unexpected ideas are often born in cross-border encounters between
cutting edge expertise and enterprise,” says Sarah Fredriksson, CEO of Genovis.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00